Plasma microRNA-155-5p is increased among patients with chronic kidney disease and nocturnal hypertension
Plasma microRNA-155-5p is increased among patients with chronic kidney disease and nocturnal hypertension
复制标题
DOI：
10.1016/j.jash.2017.10.008
复制
发表时间：
2017-12-01
影响因子：
--
通讯作者：
Paczek, Leszek
中科院分区：
文献类型：
--
作者：
Klimczak, Dominika;Kuch, Marek;Paczek, Leszek
MicroRNA 在血压 (BP) 调节中发挥多种作用。然而，迄今为止，尚无研究评估慢性肾病 (CKD) 患者血浆 microRNA 表达与血压控制之间的关联。鉴于此背景，我们评估了 CKD 患者中 miR-155-5p（I 型血管紧张素受体翻译抑制剂）的血浆表达，以确定 miR-155-5p 水平与血压控制之间的关联。在这项单中心横断面研究中，我们使用U6 snRNA作为参考基因，通过定量逆转录聚合酶链反应和24小时动态血压监测，分析了CKD患者（>=2期）与健康年龄匹配和性别匹配的健康个体的miR-155-5p浓度，通过动态血压监测证明血压正常。我们总共入组了 105 名 CKD 患者（2-5 期，包括 33 名肾移植受者），年龄 59 +/- 14 岁； 47% 为男性，26 名健康志愿者（年龄 55 +/- 13 岁，50% 为男性）。在研究组中，共有 36 名患者 (40%) 的平均 24 小时收缩压 (SBP) >= 130 mm Hg，41 名患者 (45%) 出现夜间高血压 (NHT；SBP >= 120 mm Hg 或舒张压 >= 70 mm Hg)。 CKD 患者血浆中 miRNA-155-5p 增加，相对于对照受试者，中值表达为 2.92 (1.34-5.58)。有趣的是，NHT 患者的血浆 miRNA155-5p 表达显着较高：4.04 (2.92-10.8) 与 2.01 (1.21-3.07)，P = 0.001，并且通过调整混杂因素的多变量回归分析，其表达与平均夜间 SBP 保持独立相关（系数 B = 4.368，P = 0.047）。 miR-155-5p 在 CKD 患者中升高，并且在 NHT 受试者中进一步升高。需要进一步的研究来确定这种非编码 RNA 作为非浸渍 CKD 个体潜在的新型生物标志物和治疗靶点的作用，其特征是心血管风险增加。 (C) 2017 年美国高血压学会。版权所有。
MicroRNAs play multiple roles in the regulation of blood pressure (BP). Nevertheless, to date, no study has assessed the association between microRNA plasma expression and BP control in chronic kidney disease (CKD) patients. Given this background, we evaluated the plasma expression of miR-155-5p, a translational inhibitor of angiotensin receptor type I, in CKD patients, to determine the association between miR-155-5p level and BP control. In this single-center cross-sectional study, we analyzed the miR-155-5p concentration by quantitative reverse transcriptase polymerase chain reaction using the U6 snRNA as a reference gene and 24-hour ambulatory blood pressure monitoring in CKD patients (stage >= 2) in relation to a control group of healthy age-matched and gender-matched individuals, with normal BP proven by the ambulatory blood pressure monitoring. We enrolled a total of 105 patients with CKD (stages 2-5, including 33 kidney renal transplant recipients), aged 59 +/- 14 years; 47% males and 26 healthy volunteers (aged 55 +/- 13, 50% male). Within the study group, a total of 36 patients (40%) presented with an average 24-hour systolic BP (SBP) >= 130 mm Hg and 41 patients (45%) presented nocturnal hypertension (NHT; SBP >= 120 mm Hg or diastolic BP >= 70 mm Hg). miRNA-155-5p was increased in plasma of CKD patients with median expression relative to control subjects equal to 2.92 (1.34-5.58). Interestingly, the plasma miRNA155-5p expression was significantly higher in patients with NHT: 4.04 (2.92-10.8) versus 2.01 (1.21-3.07), P = .001 and its expression maintained an independent association with the average nocturnal SBP (coefficient B = 4.368, P = .047) by a multivariate regression analysis adjusted for confounders. The miR-155-5p was increased among CKD patients and further increased among subjects presenting with NHT. Further studies are warranted to determine the role of this non-coding RNA as a potential novel biomarker and therapeutic target in the non-dipping CKD individuals, characterized by increased cardiovascular risk. (C) 2017 American Society of Hypertension. All rights reserved.